Daniel J Jackson, Leonard B Bacharier, Peter J Gergen, Lisa Gagalis, Agustin Calatroni, Stephanie Wellford, Michelle A Gill, Jeffrey Stokes, Andrew H Liu, Rebecca S Gruchalla, Robyn T Cohen, Melanie Makhija, Gurjit K Khurana Hershey, George T O'Connor, Jacqueline A Pongracic, Michael G Sherenian, Katherine Rivera-Spoljaric, Edward M Zoratti, Stephen J Teach, Meyer Kattan, Cullen M Dutmer, Haejin Kim, Carin Lamm, William J Sheehan, R Max Segnitz, Kimberly A Dill-McFarland, Cynthia M Visness, Patrice M Becker, James E Gern, Christine A Sorkness, William W Busse, Matthew C Altman
BACKGROUND: Black and Hispanic children living in urban environments in the USA have an excess burden of morbidity and mortality from asthma. Therapies directed at the eosinophilic phenotype reduce asthma exacerbations in adults, but few data are available in children and diverse populations. Furthermore, the molecular mechanisms that underlie exacerbations either being prevented by, or persisting despite, immune-based therapies are not well understood. We aimed to determine whether mepolizumab, added to guidelines-based care, reduced the number of asthma exacerbations during a 52-week period compared with guidelines-based care alone...
August 13, 2022: Lancet